Published in Parkinsons Dis on December 27, 2011
Direct conversion of fibroblasts to functional neurons by defined factors. Nature (2010) 18.76
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A (2008) 7.52
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science (1993) 6.73
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med (2003) 6.59
Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature (2002) 6.51
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A (2002) 4.20
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol (2009) 3.62
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol (2010) 3.56
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med (1992) 3.23
Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med (2004) 2.98
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord (1999) 2.98
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells (2005) 2.74
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 2.37
Functional recovery in parkinsonian monkeys treated with GDNF. Nature (1996) 2.35
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology (2005) 2.19
Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A (2007) 2.19
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol (2004) 2.11
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain (1996) 1.87
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med (2010) 1.78
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther (2010) 1.68
Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med (1989) 1.59
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci (2001) 1.57
Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci (2005) 1.51
Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol (1994) 1.50
Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord (2010) 1.47
Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord (2004) 1.45
Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci (2008) 1.43
Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord (2009) 1.43
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis (2010) 1.41
Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab (2006) 1.26
Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med (2009) 1.25
Is deep brain stimulation neuroprotective if applied early in the course of PD? Nat Clin Pract Neurol (2008) 1.21
Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med (2009) 1.20
Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol (1993) 1.19
Drug treatment of Parkinson's disease. BMJ (1995) 1.19
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther (2000) 1.18
Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain (2000) 1.18
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
The suitability of patient-based measures in the field of Parkinson's disease: a systematic review. Mov Disord (2007) 1.11
Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci (2008) 1.10
Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology (2000) 1.07
Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int (2008) 1.05
Progress and prospects: stem cells and neurological diseases. Gene Ther (2010) 1.04
Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A (2002) 1.04
Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord (1998) 1.03
Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol (1995) 1.00
Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson's disease and proposed criteria for use of sham surgery controls. J Med Ethics (2002) 0.99
Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain (2008) 0.97
Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res Bull (2004) 0.97
Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci (2001) 0.96
The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol (1999) 0.96
Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov Disord (2003) 0.93
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord (2008) 0.92
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord (2010) 0.91
Neuroimaging in Parkinson's disease. NeuroRx (2004) 0.88
Intracerebral adrenal medulla grafts: a review. Exp Neurol (1990) 0.85
Long-duration response to levodopa. Neurology (1995) 0.84
Gene therapy for dopamine replacement in Parkinson's disease. Sci Transl Med (2009) 0.81
Gene therapy: a viable therapeutic strategy for Parkinson's disease? J Neurol (2010) 0.80
Electronic motor function diary for patients with Parkinson's disease: a feasibility study. Parkinsonism Relat Disord (2006) 0.80
Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol (2013) 3.05
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg (2011) 2.53
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol (2005) 1.62
Frequency specific activity in subthalamic nucleus correlates with hand bradykinesia in Parkinson's disease. Exp Neurol (2012) 1.55
Urinary incontinence following deep brain stimulation of the pedunculopontine nucleus. Acta Neurochir (Wien) (2011) 1.46
Image-verified deep brain stimulation reduces risk and cost with no apparent impact on efficacy. Mov Disord (2012) 1.42
Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging. Neuroimage (2011) 1.33
Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest (2013) 1.32
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27
Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain (2012) 1.18
Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry (2010) 1.13
Subthalamic nucleus activity optimizes maximal effort motor responses in Parkinson's disease. Brain (2012) 1.13
Screening for VPS35 mutations in Parkinson's disease. Neurobiol Aging (2011) 1.12
UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol (2006) 1.06
Decision making, impulsivity, and addictions: do Parkinson's disease patients jump to conclusions? Mov Disord (2012) 1.03
Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord (2014) 1.02
Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs (2006) 1.01
Clinical safety of brain magnetic resonance imaging with implanted deep brain stimulation hardware: large case series and review of the literature. World Neurosurg (2011) 1.00
Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol Neurosurg Psychiatry (2010) 0.98
Minimizing brain shift in stereotactic functional neurosurgery. Neurosurgery (2010) 0.97
Complementary roles of different oscillatory activities in the subthalamic nucleus in coding motor effort in Parkinsonism. Exp Neurol (2013) 0.97
Subthalamic nucleus local field potential activity during the Eriksen flanker task reveals a novel role for theta phase during conflict monitoring. J Neurosci (2013) 0.96
Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation. Brain (2013) 0.95
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Mov Disord (2011) 0.95
A gamma band specific role of the subthalamic nucleus in switching during verbal fluency tasks in Parkinson's disease. Exp Neurol (2011) 0.90
Functional imaging of subthalamic nucleus deep brain stimulation in Parkinson's disease. Mov Disord (2011) 0.88
Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus. Mov Disord (2011) 0.87
The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci Biobehav Rev (2013) 0.87
Dopamine agonists rather than deep brain stimulation cause reflection impulsivity in Parkinson's disease. J Parkinsons Dis (2013) 0.87
Improving targeting in image-guided frame-based deep brain stimulation. Neurosurgery (2010) 0.86
The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure. Stereotact Funct Neurosurg (2012) 0.85
Predictive factors of speech intelligibility following subthalamic nucleus stimulation in consecutive patients with Parkinson's disease. Mov Disord (2014) 0.83
Early and marked benefit with GPi DBS for Lubag syndrome presenting with rapidly progressive life-threatening dystonia. Mov Disord (2009) 0.83
Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis. PLoS One (2013) 0.83
Deep brain stimulation as a treatment for chorea-acanthocytosis. J Neurol (2012) 0.82
Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation. Mov Disord (2013) 0.81
The factor structure of the UPDRS as an index of disease progression in Parkinson's disease. J Parkinsons Dis (2011) 0.80
Gene therapy: a viable therapeutic strategy for Parkinson's disease? J Neurol (2010) 0.80
Subthalamic nucleus gamma oscillations mediate a switch from automatic to controlled processing: a study of random number generation in Parkinson's disease. Neuroimage (2012) 0.80
No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease. J Neurol (2009) 0.80
A whole genome association study in multiple sclerosis patients from north Portugal. J Neuroimmunol (2003) 0.79
What You See Is What You Get: Lead Location Within Deep Brain Structures Is Accurately Depicted by Stereotactic Magnetic Resonance Imaging. Neurosurgery (2015) 0.79
Skewering the subthalamic nucleus via a parietal approach. Stereotact Funct Neurosurg (2011) 0.78
Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination. Mov Disord (2013) 0.77
A genome-wide screen for association in Hungarian multiple sclerosis. J Neuroimmunol (2003) 0.76
Can Parkinson's disease be cured by stimulating neurogenesis? J Clin Invest (2015) 0.76
No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease. Mov Disord (2006) 0.76
Image-guided and image-verified deep brain stimulation. Mov Disord (2013) 0.75
Understanding and prevention of "therapy-" induced dyskinesias. Parkinsons Dis (2012) 0.75
MRI-guided subthalamic nucleus deep brain stimulation without microelectrode recording: can we dispense with surgery under local anaesthesia? Stereotact Funct Neurosurg (2011) 0.75
Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: The Effect of Varying Stimulation Parameters. J Parkinsons Dis (2017) 0.75
The future challenges in Parkinson's disease. J Neurol (2004) 0.75